Our company's commercialization strategy is as follows
- Development of Treatments for Various Cancer Types: We plan to begin with the development of therapeutics for triple-negative breast cancer and prostate cancer, and subsequently expand to a broader range of cancer treatments.
- Global Market Entry: Based on the exceptional technological capabilities of ANGel platform, we are pursuing international market entry through collaborations with global pharmaceutical companies.
- Technology Transfer: We aim to support more pharmaceutical companies in developing new cancer therapeutics using ANGel platform through technology transfer, providing better treatment options for patients.